Cure My Disease

Don't miss your cure!

 Log in / Sign up

CBD study in 24 healthy volunteers reveals how the body absorbs it

NCT ID NCT05023070

Completed Knowledge-focused Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1 trial looked at how cannabidiol (CBD) is absorbed and processed in 24 healthy adults. Researchers gave different doses of CBD and measured its levels in blood and urine, along with any side effects. The goal was to understand the drug's pharmacokinetics, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Cannabidiol (CBD)
What this could lead to
If successful, this could help doctors understand the best way to dose CBD for future studies or medical use.
What could go wrong
This is a very early, small study in healthy people, not patients. It only looks at how the body handles CBD, not whether it treats any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.